search
Back to results

NSAIDs vs. Coxibs in the Presence of Aspirin

Primary Purpose

Rheumatoid Arthritis, Cardiovascular Diseases

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
celecoxib 200mg capsule
naproxen sodium 550mg tablet
Aspirin 81mg tablet
Sponsored by
Inova Health Care Services
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:Qualified patients should have all 4 main criteria

  1. Age 18-75 years of age for patients who regularly use NSAIDs.
  2. Age 18-65 years of age for patients who do not regularly use NSAIDs
  3. Able to give informed consent
  4. Subjects with CVD or increased CV risk. Please see definitions for each criteria below:

    • Increased CV risk (Subjects should have at least 3 of the following)

      • > 55 years of age
      • Hypertension
      • Dyslipidemia (LDL > 160 mg/dL or HDL < 40 mg/dL in females and < 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or prescription niacin [≥1,000 mg/d])
      • Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females)
      • Current smoker
      • Left ventricular hypertrophy
      • Documented ankle brachial index of <0.9
      • History of microalbuminuria, urine protein-creatinine ratio of >2
    • CV disease (defined as one of the following):

      • Calcium score of >0
      • ≥ 50 % occlusion of a coronary artery by angiography
      • ≥ 50 % occlusion of a carotid artery by angiography or ultrasound
      • History of stable angina
      • Symptomatic peripheral arterial disease
      • Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred > 3 months prior to screening visit
      • Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent).
    • Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs.

Exclusion Criteria: Subjects with any of the following criteria will be excluded from this study:

  1. Unstable angina, MI, CVA, CABG <3 months from screening visit
  2. Planned coronary, cerebrovascular, or peripheral revascularization
  3. Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period
  4. Uncontrolled hypertension (SBP >190, DBP >100 mm Hg) during screening visit
  5. Uncontrolled arrhythmia < 3 months from screening visit
  6. NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 %
  7. Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure
  8. Oral corticosteroid, prednisone (or equivalent) > 20 mg daily
  9. Anticoagulation therapy
  10. Antiplatelet therapy except for aspirin
  11. GI ulceration < 60 days before screening visit
  12. GI bleeding, perforation, obstruction < 6 months of screening visit
  13. Inflammatory bowel disease, diverticulitis active < 6 months of screening visit
  14. AST, ALT, or BUN >2x the upper limit normal (within 30 days prior to screening visit)
  15. Creatinine level >1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit)
  16. On fluconazole, methotrexate, or lithium therapy
  17. Malignancy < 5 years before screening visit
  18. Other known, active, significant GI, hepatic, renal, or coagulation disorders
  19. Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides)
  20. History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study
  21. Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate
  22. Subjects who are legally institutionalized
  23. Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal-

Sites / Locations

  • Inova Heart and Vascular InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

ASA and Celecoxib

ASA and Naproxen

Arm Description

Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)

Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)

Outcomes

Primary Outcome Measures

Platelet aggregation
Change in platelet aggregation by light transmittance aggregometry between treatment groups

Secondary Outcome Measures

Serum TxB2
Changes in serum TxB2 between treatment groups
Urine thromboxane
Changes in urine thromboxane between treatment groups
Urine 8 iso prostaglandin
Changes in urine 8 iso prostaglandin between treatment groups
Endothelial function by EndoPAT
Changes in endothelial function by EndoPAT (Endothelial Peripheral Arterial Tone) between treatment groups
Soluble markers of circulating adhesion molecules (VCAM, ICAM).
Changes in soluble markers of circulating adhesion molecules (VCAM, and ICAM) between treatment groups
hsCRP
Changes in hsCRP between treatment groups
Oxidized LDL
Changes in Oxidized LDL between treatment groups

Full Information

First Posted
September 21, 2018
Last Updated
October 4, 2018
Sponsor
Inova Health Care Services
search

1. Study Identification

Unique Protocol Identification Number
NCT03699293
Brief Title
NSAIDs vs. Coxibs in the Presence of Aspirin
Official Title
NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Recruiting
Study Start Date
September 22, 2018 (Actual)
Primary Completion Date
September 24, 2019 (Anticipated)
Study Completion Date
November 24, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Inova Health Care Services

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
Detailed Description
The relative cardiovascular safety of NSAIDs, particularly among patients with cardiovascular disease (CVD) or at higher CVD risk, has generated considerable concern among both patients and physicians because of knowledge gaps in the evidence relative to comparative safety and pharmacodynamic interactions between aspirin and NSAIDs. In the recently reported PRECISION trial, a moderate dose of celecoxib was found to be noninferior to ibuprofen or naproxen with respect to cardiovascular safety in patients with arthritis at increased CVD risk. At this time, no comparative prior data are available analyzing the effects of NSAIDs vs. Coxibs in the presence of aspirin on platelet function, biomarkers of inflammation and endothelial function. Thirty patients with rheumatoid arthritis who are at high cardiovascular (CV) risk or with established CV disease will be enrolled in the study. Patients taking anticoagulant therapy or any other antiplatelet agent other than aspirin will be excluded. Patients will be treated with immediate release 81mg aspirin for 4 weeks in the run-in period followed by randomization to celecoxib (200 mg bid) vs. naproxen sodium (550 mg bid) for 4 weeks and then cross over to the other drug for another 4 weeks. Blood and urine samples will be collected at baseline before the aspirin run in period, 24±4 hr after the last dose of aspirin in the run in period, 24±4 hr after the last dose of the first period study drug and 24±4 hr after the last dose of the second period study drug. Assays for platelet function, biomarkers of inflammation and endothelial function will be performed at these time points.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis, Cardiovascular Diseases

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Model Description
Qualified patients will be treated with immediate release 81mg aspirin for 4 weeks in the run-in period followed by randomization to celecoxib (200 mg bid) vs. naproxen sodium (550 mg bid) for 4 weeks and then cross over to the other drug for another 4 weeks. Blood and urine samples will be collected before the aspirin run-in period (baseline), 24±4 hrs after the last dose of aspirin in the run-in period, 24±4 hr after the last dose of the study drug in the first period and 24±4 hr after the last dose of the study drug in the second period. Assays for platelet function, biomarkers of inflammation and endothelial function will be performed at these time points
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ASA and Celecoxib
Arm Type
Active Comparator
Arm Description
Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
Arm Title
ASA and Naproxen
Arm Type
Active Comparator
Arm Description
Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
Intervention Type
Drug
Intervention Name(s)
celecoxib 200mg capsule
Other Intervention Name(s)
Celebrex
Intervention Description
celecoxib 200mg twice a day for 4 weeks
Intervention Type
Drug
Intervention Name(s)
naproxen sodium 550mg tablet
Other Intervention Name(s)
Aleve, Naprosyn
Intervention Description
naproxen sodium 550mg twice a day for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Aspirin 81mg tablet
Other Intervention Name(s)
Bayer Aspirin
Intervention Description
81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
Primary Outcome Measure Information:
Title
Platelet aggregation
Description
Change in platelet aggregation by light transmittance aggregometry between treatment groups
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Serum TxB2
Description
Changes in serum TxB2 between treatment groups
Time Frame
12 weeks
Title
Urine thromboxane
Description
Changes in urine thromboxane between treatment groups
Time Frame
12 weeks
Title
Urine 8 iso prostaglandin
Description
Changes in urine 8 iso prostaglandin between treatment groups
Time Frame
12 weeks
Title
Endothelial function by EndoPAT
Description
Changes in endothelial function by EndoPAT (Endothelial Peripheral Arterial Tone) between treatment groups
Time Frame
12 weeks
Title
Soluble markers of circulating adhesion molecules (VCAM, ICAM).
Description
Changes in soluble markers of circulating adhesion molecules (VCAM, and ICAM) between treatment groups
Time Frame
12 weeks
Title
hsCRP
Description
Changes in hsCRP between treatment groups
Time Frame
12 weeks
Title
Oxidized LDL
Description
Changes in Oxidized LDL between treatment groups
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:Qualified patients should have all 4 main criteria Age 18-75 years of age for patients who regularly use NSAIDs. Age 18-65 years of age for patients who do not regularly use NSAIDs Able to give informed consent Subjects with CVD or increased CV risk. Please see definitions for each criteria below: Increased CV risk (Subjects should have at least 3 of the following) > 55 years of age Hypertension Dyslipidemia (LDL > 160 mg/dL or HDL < 40 mg/dL in females and < 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or prescription niacin [≥1,000 mg/d]) Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females) Current smoker Left ventricular hypertrophy Documented ankle brachial index of <0.9 History of microalbuminuria, urine protein-creatinine ratio of >2 CV disease (defined as one of the following): Calcium score of >0 ≥ 50 % occlusion of a coronary artery by angiography ≥ 50 % occlusion of a carotid artery by angiography or ultrasound History of stable angina Symptomatic peripheral arterial disease Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred > 3 months prior to screening visit Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent). Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs. Exclusion Criteria: Subjects with any of the following criteria will be excluded from this study: Unstable angina, MI, CVA, CABG <3 months from screening visit Planned coronary, cerebrovascular, or peripheral revascularization Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period Uncontrolled hypertension (SBP >190, DBP >100 mm Hg) during screening visit Uncontrolled arrhythmia < 3 months from screening visit NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 % Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure Oral corticosteroid, prednisone (or equivalent) > 20 mg daily Anticoagulation therapy Antiplatelet therapy except for aspirin GI ulceration < 60 days before screening visit GI bleeding, perforation, obstruction < 6 months of screening visit Inflammatory bowel disease, diverticulitis active < 6 months of screening visit AST, ALT, or BUN >2x the upper limit normal (within 30 days prior to screening visit) Creatinine level >1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit) On fluconazole, methotrexate, or lithium therapy Malignancy < 5 years before screening visit Other known, active, significant GI, hepatic, renal, or coagulation disorders Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides) History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate Subjects who are legally institutionalized Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Bliden, BS, MBA
Phone
(703) 776-7702
Email
kevin.bliden@inova.org
First Name & Middle Initial & Last Name or Official Title & Degree
Emiliya Bakalska, BA
Phone
(410) 367-2592
Email
emiliya.bakalska@inova.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Bliden, BS, MBA
Organizational Affiliation
Inova Health Care Services
Official's Role
Study Director
Facility Information:
Facility Name
Inova Heart and Vascular Institute
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Fitzgerald, RN, MS
Phone
703-776-3330
Email
andrea.fitzgerald@inova.org
First Name & Middle Initial & Last Name & Degree
Solomon Yeon, MS
Phone
(703) 776-4726
Email
solomon.yeaon@inova.org

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share IPD.

Learn more about this trial

NSAIDs vs. Coxibs in the Presence of Aspirin

We'll reach out to this number within 24 hrs